Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kamal Mohamadian"'
Autor:
Abdolazim Sedighi Pashaki, Ehsan Akbari Hamed, Kamal Mohamadian, Mohammad Abassi, Afsane Maddah Safaei, Mohammad Babaei, Mohammad Hadi Gholami, Ali Reza Khoshghadam
Publikováno v:
Middle East Journal of Cancer, Vol 5, Iss 2, Pp 91-96 (2014)
Background: Central nervous system tumors account for 2%-5% of all malignancies in humans. These tumors account for 2% of all pediatric cancers. The worldwide incidence of primary central nervous system tumors is estimated at 3.9 (males) and 3.2 (
Externí odkaz:
https://doaj.org/article/1bf352f3354a4e14b372139427c664ab
Autor:
Masoumeh Rezaii, Arash Moradi, Kamal Mohamadian, Aida Alizamir, Seyed Ahmad Aleyasin, Behrouz Afshar
BackgroundGastric cancer (GC) is the fifth most prevalent cancer, and intestinal metaplasia (IM) is generally considered a precancerous lesion in the gastric carcinogenesis cascade. DNA methylation is one of the most deeply studied epigenetic modific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eae5c0cb7fdc7c19ce427cfea8714b04
https://doi.org/10.21203/rs.3.rs-156439/v1
https://doi.org/10.21203/rs.3.rs-156439/v1
Autor:
Afsane Maddah Safaei, Abdolazim Sedighi Pashaki, Kamal Mohamadian, Mohammad Abassi, Tayebe Torkaman, Ehsan Akbari Hamed
Publikováno v:
Asian Pacific journal of cancer prevention : APJCP. 15(6)
Background: Glioblastoma multiform (GBM) is a highly aggressive tumor with median survival of approximately 14 months. Management consists of maximal surgical resection followed by post-operative chemoradiation with concurrent then adjuvant temozolam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a8ab3cf979d24bfdd979b31ca3d3ff1
https://pubmed.ncbi.nlm.nih.gov/24761902
https://pubmed.ncbi.nlm.nih.gov/24761902
Autor:
Kamal Mohamadian, A. Sedighi Pashaki, E. Akbari Hamed, A. Maddah Safaei, Mohammad Abassi, Mohammad Gholami
Publikováno v:
European Journal of Cancer. 50:e34
Background Glioblastoma multiforme is a highly aggressive tumour with median survival of approximately 14 months. Management consists of maximal surgical resection followed by postoperative chemoradiation with concurrent then adjuvant temozolamide. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d348107736726e7ec83b76129fd1ea00
https://doi.org/10.1016/j.ejca.2014.03.132
https://doi.org/10.1016/j.ejca.2014.03.132